Alexander Alexiou, MB, BS, BSc, DCH, FRCEM, Dip IMC RCSEd
Greater Sydney Area Helicopter Emergency Medical Service
AA declares that he has no competing interests.
BMJ Best Practice would like to gratefully acknowledge the previous team of expert contributors, whose work is retained in parts of the content:
Jason J Rose, MD, MBA
Assistant Professor of Medicine and Biomedical Engineering
University of Pittsburgh
Disclosures: JJR is a co-inventor on patent applications for the use of heme-based molecules as antidotes for CO poisoning. JJR is a shareholder, officer, and director of Globin Solutions, Inc. Globin Solutions, Inc. has an exclusive license to this technology. Globin Solutions, Inc. had an option agreement to technology directed at using hydroxycobalamin for CO poisoning from Virginia Commonwealth University in the last 12 months. JJR is an author of publications cited within this topic.
Robert Taylor, MBChB, MRCP(UK), MRCP(London), DipMedTox, DipTher PGDME, FHEA FRCEM
Acute Hospital Sub Dean (Cornwall)
Honorary Clinical Senior Lecturer
Consultant Emergency Physician
University of Exeter Medical School
Royal Cornwall Hospitals NHS trust
RT declares that he has no competing interests.
Section Editor, BMJ Best Practice
EQ declares that she has no competing interests.
Lead Section Editor, BMJ Best Practice
TAO declares that she has no competing interests.
Comorbidities Editor, BMJ Best Practice
JC declares that she has no competing interests.
Drug Editor, BMJ Best Practice
AM declares that he has no competing interests.